Xenon Pharmaceuticals, which licenses drugs to uniQure, Teva and Genentech for LPLD, pain and acne, raised $36 million by offering 4 million shares at $9, below the range of $10 to $12. Xenon Pharmaceuticals plans to list on the NASDAQ under the symbol XENE. Xenon Pharmaceuticals initially filed confidentially on 8/16/2013. Jefferies & Co. and Wells Fargo Securities acted as lead managers on the deal.
